FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153156618> ?p ?o ?g. }

• W2153156618 endingPage "85" @default.
• W2153156618 startingPage "80" @default.
• W2153156618 abstract "To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992. An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored. Thirty-eight patients were enrolled. Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg. At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhoea despite treatment with loperamide) occurred in two patients. In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients. An intermediate dose level of 85 mg was studied. Here DLT occurred in two patients (grade 3 diarrhoea despite treatment and grade 2 diarrhoea lasting more than 7 days despite treatment). An additional 12 patients were treated at 70 mg. BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality. Pharmacodynamics analysis in skin biopsies did not show significant changes in EGFR-associated biomarkers. However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was observed. No partial or complete responses were observed, stable disease lasting more than four cycles was seen in seven patients. The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD." @default.
• W2153156618 created "2016-06-24" @default.
• W2153156618 creator A5011819733 @default.
• W2153156618 creator A5016301942 @default.
• W2153156618 creator A5021449457 @default.
• W2153156618 creator A5041442043 @default.
• W2153156618 creator A5044081105 @default.
• W2153156618 creator A5047685910 @default.
• W2153156618 creator A5049091553 @default.
• W2153156618 creator A5058280049 @default.
• W2153156618 creator A5068372434 @default.
• W2153156618 creator A5071612016 @default.
• W2153156618 creator A5085868795 @default.
• W2153156618 date "2007-11-20" @default.
• W2153156618 modified "2023-10-14" @default.
• W2153156618 title "A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours" @default.
• W2153156618 cites W1482218984 @default.
• W2153156618 cites W1974024530 @default.
• W2153156618 cites W1974208182 @default.
• W2153156618 cites W2035490834 @default.
• W2153156618 cites W2092104789 @default.
• W2153156618 cites W2104220103 @default.
• W2153156618 cites W2104263132 @default.
• W2153156618 cites W2110444464 @default.
• W2153156618 cites W2111399814 @default.
• W2153156618 cites W2126314379 @default.
• W2153156618 cites W2132154923 @default.
• W2153156618 cites W2132557004 @default.
• W2153156618 cites W2135836172 @default.
• W2153156618 cites W2139248078 @default.
• W2153156618 cites W2139916512 @default.
• W2153156618 cites W2142752401 @default.
• W2153156618 cites W2143877481 @default.
• W2153156618 cites W2163283029 @default.
• W2153156618 cites W2167368130 @default.
• W2153156618 cites W2169816570 @default.
• W2153156618 doi "https://doi.org/10.1038/sj.bjc.6604108" @default.
• W2153156618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2359721" @default.
• W2153156618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18026190" @default.
• W2153156618 hasPublicationYear "2007" @default.
• W2153156618 type Work @default.
• W2153156618 sameAs 2153156618 @default.
• W2153156618 citedByCount "213" @default.
• W2153156618 countsByYear W21531566182012 @default.
• W2153156618 countsByYear W21531566182013 @default.
• W2153156618 countsByYear W21531566182014 @default.
• W2153156618 countsByYear W21531566182015 @default.
• W2153156618 countsByYear W21531566182016 @default.
• W2153156618 countsByYear W21531566182017 @default.
• W2153156618 countsByYear W21531566182018 @default.
• W2153156618 countsByYear W21531566182019 @default.
• W2153156618 countsByYear W21531566182020 @default.
• W2153156618 countsByYear W21531566182021 @default.
• W2153156618 countsByYear W21531566182022 @default.
• W2153156618 countsByYear W21531566182023 @default.
• W2153156618 crossrefType "journal-article" @default.
• W2153156618 hasAuthorship W2153156618A5011819733 @default.
• W2153156618 hasAuthorship W2153156618A5016301942 @default.
• W2153156618 hasAuthorship W2153156618A5021449457 @default.
• W2153156618 hasAuthorship W2153156618A5041442043 @default.
• W2153156618 hasAuthorship W2153156618A5044081105 @default.
• W2153156618 hasAuthorship W2153156618A5047685910 @default.
• W2153156618 hasAuthorship W2153156618A5049091553 @default.
• W2153156618 hasAuthorship W2153156618A5058280049 @default.
• W2153156618 hasAuthorship W2153156618A5068372434 @default.
• W2153156618 hasAuthorship W2153156618A5071612016 @default.
• W2153156618 hasAuthorship W2153156618A5085868795 @default.
• W2153156618 hasBestOaLocation W21531566181 @default.
• W2153156618 hasConcept C111113717 @default.
• W2153156618 hasConcept C112705442 @default.
• W2153156618 hasConcept C121608353 @default.
• W2153156618 hasConcept C126322002 @default.
• W2153156618 hasConcept C197934379 @default.
• W2153156618 hasConcept C2778375690 @default.
• W2153156618 hasConcept C2778570526 @default.
• W2153156618 hasConcept C2778820342 @default.
• W2153156618 hasConcept C2779438470 @default.
• W2153156618 hasConcept C29730261 @default.
• W2153156618 hasConcept C71924100 @default.
• W2153156618 hasConcept C90924648 @default.
• W2153156618 hasConcept C98274493 @default.
• W2153156618 hasConceptScore W2153156618C111113717 @default.
• W2153156618 hasConceptScore W2153156618C112705442 @default.
• W2153156618 hasConceptScore W2153156618C121608353 @default.
• W2153156618 hasConceptScore W2153156618C126322002 @default.
• W2153156618 hasConceptScore W2153156618C197934379 @default.
• W2153156618 hasConceptScore W2153156618C2778375690 @default.
• W2153156618 hasConceptScore W2153156618C2778570526 @default.
• W2153156618 hasConceptScore W2153156618C2778820342 @default.
• W2153156618 hasConceptScore W2153156618C2779438470 @default.
• W2153156618 hasConceptScore W2153156618C29730261 @default.
• W2153156618 hasConceptScore W2153156618C71924100 @default.
• W2153156618 hasConceptScore W2153156618C90924648 @default.
• W2153156618 hasConceptScore W2153156618C98274493 @default.
• W2153156618 hasIssue "1" @default.
• W2153156618 hasLocation W21531566181 @default.
• W2153156618 hasLocation W21531566182 @default.
• W2153156618 hasLocation W21531566183 @default.

• next